Genscript Biotech Future Growth

Future criteria checks 5/6

Genscript Biotech is forecast to grow earnings and revenue by 92.5% and 36.9% per annum respectively. EPS is expected to grow by 94.9% per annum. Return on equity is forecast to be 18.2% in 3 years.

Key information

92.5%

Earnings growth rate

94.9%

EPS growth rate

Life Sciences earnings growth	25.8%
Revenue growth rate	36.9%
Future return on equity	18.2%
Analyst coverage	Good
Last updated	25 Mar 2024

Recent future growth updates

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Recent updates

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Dec 05

Earnings and Revenue Growth Forecasts

SEHK:1548 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,776	389	-55	846	7
12/31/2025	1,920	28	-96	74	11
12/31/2024	1,281	-103	-346	-112	11
12/31/2023	840	-95	-543	-287	N/A
9/30/2023	773	-140	-506	-266	N/A
6/30/2023	707	-185	-470	-245	N/A
3/31/2023	667	-206	-404	-183	N/A
12/31/2022	626	-227	-339	-120	N/A
9/30/2022	598	-315	-321	-142	N/A
6/30/2022	570	-403	-304	-163	N/A
3/31/2022	530	-381	-289	-150	N/A
12/31/2021	490	-359	-274	-137	N/A
9/30/2021	483	-265	-265	-127	N/A
6/30/2021	454	-183	-256	-118	N/A
3/31/2021	422	-194	-268	-134	N/A
12/31/2020	391	-205	-279	-151	N/A
9/30/2020	354	-194	-171	-48	N/A
6/30/2020	318	-183	-64	54	N/A
3/31/2020	296	-140	-103	12	N/A
12/31/2019	273	-97	-142	-30	N/A
9/30/2019	257	-59	-207	-116	N/A
6/30/2019	241	-22	-272	-202	N/A
3/31/2019	236	0	-18	53	N/A
12/31/2018	231	21	236	308	N/A
9/30/2018	216	24	266	338	N/A
6/30/2018	201	27	297	369	N/A
3/31/2018	177	26	144	195	N/A
12/31/2017	153	26	-8	21	N/A
9/30/2017	139	27	N/A	24	N/A
6/30/2017	125	28	N/A	27	N/A
3/31/2017	120	27	N/A	30	N/A
12/31/2016	115	26	N/A	33	N/A
9/30/2016	107	26	N/A	29	N/A
6/30/2016	99	25	N/A	25	N/A
3/31/2016	93	21	N/A	22	N/A
12/31/2015	87	18	N/A	20	N/A
9/30/2015	82	13	N/A	18	N/A
6/30/2015	78	8	N/A	16	N/A
3/31/2015	74	7	N/A	14	N/A
12/31/2014	70	6	N/A	12	N/A
12/31/2013	60	6	N/A	12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1548 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: 1548 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 1548 is expected to become profitable in the next 3 years.

Revenue vs Market: 1548's revenue (36.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).

High Growth Revenue: 1548's revenue (36.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1548's Return on Equity is forecast to be low in 3 years time (18.2%).

Genscript Biotech Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Consensus revenue estimates fall by 19%

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Consensus forecasts updated

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated

Key Executive exercised options and sold HK$897k worth of stock

Board Member exercised options and sold HK$1.1m worth of stock

Board Member recently sold HK$2.1m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Co-Founder exercised options and sold HK$93m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Key Executive recently sold HK$9.1m worth of stock

Co-Founder exercised options and sold HK$165m worth of stock

Co-Founder exercised options and sold HK$72m worth of stock

Co-Founder exercised options and sold HK$74m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Is Genscript Biotech Corporation (HKG:1548) Trading At A 49% Discount?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)